Abstract 295P
Background
Volumetric arc therapy (VMAT) with Simultaneous Integrated Boost (SIB) allows radiotherapy dose escalation to the region of involved nodes also reducing toxicity in node-positive patients of cervical cancer. Aim of this study was to evaluate the early outcome and acute toxicity with chemo-radiation usingVMAT with SIB in patients with locally advanced cervical cancer.
Methods
Thirty-three newly diagnosed cases of carcinoma cervix having Positron emission tomography (PET) positive pelvic/para-aortic nodes were included after obtaining a written informed consent. The complete clinical assessment and staging was performed. All patients were treated by VMAT with SIB technique to the dose of 50.4Gy to the primary site with draining nodes and 58.8Gy to PET positive nodes in 28 fractions followed by HDR brachytherapy boost of 7Gy in three fractions. Concurrent cisplatin at the dose of 40mg/m2 was administered on weekly basis during External beam radiotherapy. Acute toxicity was assessed according to the RTOG Acute Radiation Morbidity scoring criteria. Post treatment response was assessed by clinical examination and PET-CT /CECT scans at 3months.
Results
Median age was 55 years(range 35-70). The mean tumor size was 5.7cm (range 3.5-9) with 90% patients having disease more than 4cm. Median Standardized uptake value maximum in PET at primary tumor and LN was 17.3 and 8.7 respectively. Pelvic node only was seen in 23(69.6%) patients while Para-aortic node was involved in ten. Bladder and rectum invasion was seen in four and two patients respectively.Twenty-six (79%) patients received four or more cycles of concurrent Cisplatin. The median overall treatment time was 62 days. Response assessment at 3months showed complete response in 27 patients (82%), partial response in four while progressive disease in two patients. Maximum grade of toxicity at 3 months in skin, gastrointestinal, and hematological was grade I whereas one patient had grade III genitourinary toxicity. At last follow up, 30 patients were alive while three patients died; two deaths due to disease.
Conclusions
VMAT with SIB to involved nodes to higher doses results in effective early loco-regional control with acceptable acute toxicities.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
R. Mishra.
Funding
Institute of Eminence, Banaras Hindu University, Varanasi.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract